[
  {
    "sentence": "Results\nMulti-omics colocalization analysis reveals key genetic variants in brain cancer\neQTL analysis indicates that CDKN2A, CDKN2B, and CDKN2B-AS1 co-locate with brain cancer(Fig. 1A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additional co-localization statistics are provided in Table 1. (I, J) The loci of the CDKN2B-AS1 and TERT genes are explored for their genetic correlations with diseases associated with these loci.mQTL analysis reveals that TERT, AL359922.1, and CDKN2B co-locate with brain cancer(Fig. 1D, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "ID\nMolecule\nProbe\nGene_id\nChr\nnsnps\npp_h4_abf\npp4_pp3\nColoc_snp\n\n\n\nieu-b-4875\neQTL\nENSG00000240498.9\nCDKN2B-AS1\n9\n2722\n0.951\n19.330\nrs613312\n\n\n\n\nENSG00000147889\nCDKN2A\n9\n2372\n0.917\n11.047\nrs523096\n\n\n\n\nENSG00000147883.12\nCDKN2B\n9\n2722\n0.906\n9.651\nrs7030641\n\n\n\nmQTL\ncg03935379\nTERT\n5\n228\n0.976\n39.965\nrs7726159\n\n\n\n\ncg14069088\nAL359922.1\n9\n162\n0.971\n33.636\nrs615552\n\n\n\n\ncg00624418\nTERT\n5\n232\n0.969\n31.655\nrs7726159\n\n\n\n\ncg08390209\nAL359922.1\n9\n270\n0.723\n2.611\nrs523096\n\n\n\n\ncg08390209\nCDKN2B\n9\n270\n0.723\n2.611\nrs523096\n\n\n\nhaQTL\npeak24709\nAL359922.1\n9\n2372\n0.802\n8.735\nrs615552\n\n\n\n\npeak24709\nCDKN2A\n9\n2372\n0.802\n8.735\nrs615552\n\n\n\nsQTL\nchr9:21,995,161:22,046,751\nCDKN2B-AS1\n9\n2451\n0.786\n3.675\nrs679038\n\n\n\n\nchr9:21,995,161:22,046,751\nRP11-149I2.4\n9\n2451\n0.786\n3.675\nrs679038\n\n\n\ncaQTL\nchr9_22052542_22052842\nAL359922.1\n9\n170\n0.829\n21.247\nrs615552\n\n\n\nOpen in a new tabsQTL analysis indicates that in the Pituitary_sQTL dataset, rs615552_AL359922.1 co-localizes with the non-coding genes CDKN2B-AS1 and RP11-149I2.4 (coloc_snp: rs679038, PP4 = 0.786, PP4/PP3 = 3.68)(Fig. 1G, H).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We analyzed the loci of the CDKN2B-AS1 and TERT genes and explored the genetic correlations with diseases associated with these loci (Fig. 1I, J).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "These findings provide important clues for further research into the specific functional mechanisms of these SNPs and genes in brain cancer and other diseases, potentially aiding in the development of new therapeutic strategies and diagnostic methods.Copy number and methylation signatures of CDKN2A, CDKN2B, and TERT in brain cancer prognosis\nIn the TCGA-LGG/GBM cohorts, we compared the copy number variations (CNVs) and other modal information for the genes CDKN2A, CDKN2B, and TERT (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, Hete.Amp. was significantly more prevalent in GBM compared to LGG (Fig. 2B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The impact of these methylation sites on CNV levels, gene expression, and their correlation with survival metrics is detailed.Next, we analyzed the relationship between CDKN2A, CDKN2B, and TERT CNVs and prognosis in LGG and GBM (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, CDKN2A and CDKN2B showed a positive correlation between CNV and mRNA expression in both LGG and GBM, indicating that CNV increases (such as amplifications) were generally accompanied by elevated mRNA expression levels (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By comparing the methylation signatures of CDKN2A, CDKN2B, and TERT in the TCGA-LGG/GBM cohorts, we found that the average methylation level of CDKN2A was a favorable prognostic factor in LGG (DFI, DSS, OS, PFS) (Fig. 2F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We further investigated the relationship between gene expression regulation and methylation for these three genes (Fig. 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "High methylation of cg03935379 (TERT) was a favorable prognostic factor for LGG patients (P < 0.001, HR = 0.5, 95% CI: 0.35–0.7) and a non-significant favorable factor for GBM patients (P < 0.1, HR = 0.72, 95% CI: 0.49–1.06) (Fig. 2H-Y).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel H",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We found that these genes exhibit co-occurrence in all three cohorts (Log2 Odds Ratio > 3, q-Value < 0.001)(Table S1, Fig. 3A, Fig. 3D, Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CDKN2B-AS1, being a non-coding RNA, does not function by encoding proteins but likely participates in the post-transcriptional regulation of CDKN2A and CDKN2B, indirectly affecting the expression regulation of these cell cycle regulatory genes, given their colocation in the same genetic locus (Fig. 1I).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nGenetic Alterations and Expression Correlations of CDKN2A, CDKN2B, and CDKN2B-AS1. (A) Analysis of genetic alterations in CDKN2A, CDKN2B, and CDKN2B-AS1 in the TCGA-GBM cohort. (B, C) Correlation of CDKN2B-AS1 expression with CDKN2A and CDKN2B gene expression in the TCGA-GBM cohort. (D) Analysis of genetic alterations in CDKN2A, CDKN2B, and CDKN2B-AS1 in the TCGA-LGG cohort. (E, F) Correlation of CDKN2B-AS1 expression with CDKN2A and CDKN2B gene expression in the TCGA-LGG cohort.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, deep deletions significantly reduced the expression of CDKN2A, CDKN2B, and CDKN2B-AS1, aligning with our previous findings(Fig. 3B, C, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarly, CDKN2B-AS1 gene expression is significantly positively correlated with CDKN2B gene expression (Spearman Cor = 0.80, Pearson Cor = 0.83, P < 0.001) and protein expression (Spearman Cor = 0.59, Pearson Cor = 0.63, P < 0.001)(Fig. 4B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, these correlations were not consistent across different algorithms and cohorts(Fig. 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The positive correlation of CDKN2B-AS1 with antigen presentation-related genes indicates that high CDKN2B-AS1 expression may enhance tumor cell recognition by the immune system, particularly in LGG, suggesting a specific role in low-grade gliomas(Fig. 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "KEGG pathway analysis showed that the high CDKN2B-AS1 expression group is enriched in apoptosis, DNA replication, adipocytokine signaling, and Toll-like receptor signaling pathways, while the low expression group is enriched in calcium signaling, ErbB signaling, glioma, and long-term depression pathways(Fig. 5C, D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Overall, high CDKN2B-AS1 expression is associated with enhanced cell growth, immune activation, and apoptosis, suggesting a role in tumor progression, whereas low expression is linked to neural signaling processes, potentially affecting the tumor microenvironment.Comparing gene alterations between the two groups revealed no significant differences in frequently mutated genes and chromosomal regions(Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, low CDKN2B-AS1 expression is associated with neural and calcium signaling processes, potentially impacting the neural microenvironment of tumors(Fig. 5F-I).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Immunomodulator analysis also showed inconsistent results regarding the correlation between CDKN2B-AS1 and immune cell infiltration and immune-related pathways in GBM cohorts.In the TCGA-LGG and TCGA-GBM cohorts, we explored the correlation between CDKN2B-AS1 expression and genes related to RNA modifications (m1A, m5C, m6A)(Fig. 6A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "KEGG analysis revealed that the high expression group is enriched in cell cycle, oocyte meiosis, mTOR signaling, DNA replication, and mismatch repair pathways, while the low expression group is enriched in p53 signaling, fatty acid degradation, and drug metabolism-cytochrome P450 pathways(Fig. 6D, E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "CDKN2B-AS1 may enhance tumor cell proliferation through its regulation of DNA replication and cell cycle processes, supported by consistent results across GO, KEGG, and Hallmark analyses.In GBM, the high CDKN2B-AS1 expression group exhibited higher mutation rates in TP53, SPTA1, and RB1, with more frequent copy number losses at 12q.14.1 and 17p.13.1, and more frequent copy number gains at 9p21.3(Fig. 6F).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The consistent results from GO, KEGG, and Hallmark gene set GSEA analyses support the importance of CDKN2B-AS1 in DNA replication, cell cycle regulation, and DNA repair(Fig. 6G-J).Distribution characteristics of the glioma susceptibility lncRNA CDKN2B-AS1 in single-cell and spatial transcriptomics\nTo explore the spatial heterogeneity of CDKN2B-AS1, we analyzed its expression in 15 glioma single-cell cohorts from the TISCH2 database, which includes Glioma_GSE102130, Glioma_GSE103224, Glioma_GSE131928_10X, Glioma_GSE131928_Smartseq2, Glioma_GSE135437, Glioma_GSE141383, Glioma_GSE141460, Glioma_GSE141982, Glioma_GSE148842, Glioma_GSE162631, Glioma_GSE163108_10X, Glioma_GSE163108_Smartseq2, Glioma_GSE70630, Glioma_GSE84465, and Glioma_GSE89567.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel G",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The results indicate that CDKN2B-AS1 is predominantly enriched in Mono/Macro (10/15), AC-like Malignant (7/15), and Oligodendrocyte (7/15) cells(Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In this spatial transcriptomics dataset, 18 clusters (Morphological adjusted clusters) and 10 cell types (TumorCells, CD4TCells, CD8TCells, NKCells, Macrophages, DCs, Neutrophils, EndothelialCells, Fibroblasts, and CNSCells) were identified(Fig. 7B-D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "This result aligns with our earlier observations that CDKN2B-AS1 expression is positively correlated with antigen presentation-related genes and is localized to Mono/Macro cells at the single-cell level(Fig. 7E-H).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Multi-omics colocalization analysis reveals key genetic variants in brain cancer\neQTL analysis indicates that CDKN2A, CDKN2B, and CDKN2B-AS1 co-locate with brain cancer(Fig. 1A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Additional co-localization statistics are provided in Table 1. (I, J) The loci of the CDKN2B-AS1 and TERT genes are explored for their genetic correlations with diseases associated with these loci.mQTL analysis reveals that TERT, AL359922.1, and CDKN2B co-locate with brain cancer(Fig. 1D, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "ID\nMolecule\nProbe\nGene_id\nChr\nnsnps\npp_h4_abf\npp4_pp3\nColoc_snp\n\n\n\nieu-b-4875\neQTL\nENSG00000240498.9\nCDKN2B-AS1\n9\n2722\n0.951\n19.330\nrs613312\n\n\n\n\nENSG00000147889\nCDKN2A\n9\n2372\n0.917\n11.047\nrs523096\n\n\n\n\nENSG00000147883.12\nCDKN2B\n9\n2722\n0.906\n9.651\nrs7030641\n\n\n\nmQTL\ncg03935379\nTERT\n5\n228\n0.976\n39.965\nrs7726159\n\n\n\n\ncg14069088\nAL359922.1\n9\n162\n0.971\n33.636\nrs615552\n\n\n\n\ncg00624418\nTERT\n5\n232\n0.969\n31.655\nrs7726159\n\n\n\n\ncg08390209\nAL359922.1\n9\n270\n0.723\n2.611\nrs523096\n\n\n\n\ncg08390209\nCDKN2B\n9\n270\n0.723\n2.611\nrs523096\n\n\n\nhaQTL\npeak24709\nAL359922.1\n9\n2372\n0.802\n8.735\nrs615552\n\n\n\n\npeak24709\nCDKN2A\n9\n2372\n0.802\n8.735\nrs615552\n\n\n\nsQTL\nchr9:21,995,161:22,046,751\nCDKN2B-AS1\n9\n2451\n0.786\n3.675\nrs679038\n\n\n\n\nchr9:21,995,161:22,046,751\nRP11-149I2.4\n9\n2451\n0.786\n3.675\nrs679038\n\n\n\ncaQTL\nchr9_22052542_22052842\nAL359922.1\n9\n170\n0.829\n21.247\nrs615552\n\n\n\nOpen in a new tabsQTL analysis indicates that in the Pituitary_sQTL dataset, rs615552_AL359922.1 co-localizes with the non-coding genes CDKN2B-AS1 and RP11-149I2.4 (coloc_snp: rs679038, PP4 = 0.786, PP4/PP3 = 3.68)(Fig. 1G, H).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "eQTL analysis indicates that CDKN2A, CDKN2B, and CDKN2B-AS1 co-locate with brain cancer(Fig. 1A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "mQTL analysis reveals that TERT, AL359922.1, and CDKN2B co-locate with brain cancer(Fig. 1D, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel D",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "sQTL analysis indicates that in the Pituitary_sQTL dataset, rs615552_AL359922.1 co-localizes with the non-coding genes CDKN2B-AS1 and RP11-149I2.4 (coloc_snp: rs679038, PP4 = 0.786, PP4/PP3 = 3.68)(Fig. 1G, H).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel G",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We analyzed the loci of the CDKN2B-AS1 and TERT genes and explored the genetic correlations with diseases associated with these loci (Fig. 1I, J).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "We analyzed the loci of the CDKN2B-AS1 and TERT genes and explored the genetic correlations with diseases associated with these loci (Fig. 1I, J).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Copy number and methylation signatures of CDKN2A, CDKN2B, and TERT in brain cancer prognosis\nIn the TCGA-LGG/GBM cohorts, we compared the copy number variations (CNVs) and other modal information for the genes CDKN2A, CDKN2B, and TERT (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, Hete.Amp. was significantly more prevalent in GBM compared to LGG (Fig. 2B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The impact of these methylation sites on CNV levels, gene expression, and their correlation with survival metrics is detailed.Next, we analyzed the relationship between CDKN2A, CDKN2B, and TERT CNVs and prognosis in LGG and GBM (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, CDKN2A and CDKN2B showed a positive correlation between CNV and mRNA expression in both LGG and GBM, indicating that CNV increases (such as amplifications) were generally accompanied by elevated mRNA expression levels (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By comparing the methylation signatures of CDKN2A, CDKN2B, and TERT in the TCGA-LGG/GBM cohorts, we found that the average methylation level of CDKN2A was a favorable prognostic factor in LGG (DFI, DSS, OS, PFS) (Fig. 2F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We further investigated the relationship between gene expression regulation and methylation for these three genes (Fig. 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "High methylation of cg03935379 (TERT) was a favorable prognostic factor for LGG patients (P < 0.001, HR = 0.5, 95% CI: 0.35–0.7) and a non-significant favorable factor for GBM patients (P < 0.1, HR = 0.72, 95% CI: 0.49–1.06) (Fig. 2H-Y).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel H",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In the TCGA-LGG/GBM cohorts, we compared the copy number variations (CNVs) and other modal information for the genes CDKN2A, CDKN2B, and TERT (Fig. 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "However, Hete.Amp. was significantly more prevalent in GBM compared to LGG (Fig. 2B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Next, we analyzed the relationship between CDKN2A, CDKN2B, and TERT CNVs and prognosis in LGG and GBM (Fig. 2D).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, CDKN2A and CDKN2B showed a positive correlation between CNV and mRNA expression in both LGG and GBM, indicating that CNV increases (such as amplifications) were generally accompanied by elevated mRNA expression levels (Fig. 2E).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel E",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "By comparing the methylation signatures of CDKN2A, CDKN2B, and TERT in the TCGA-LGG/GBM cohorts, we found that the average methylation level of CDKN2A was a favorable prognostic factor in LGG (DFI, DSS, OS, PFS) (Fig. 2F).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel F",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We further investigated the relationship between gene expression regulation and methylation for these three genes (Fig. 2G).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel G",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "High methylation of cg03935379 (TERT) was a favorable prognostic factor for LGG patients (P < 0.001, HR = 0.5, 95% CI: 0.35–0.7) and a non-significant favorable factor for GBM patients (P < 0.1, HR = 0.72, 95% CI: 0.49–1.06) (Fig. 2H-Y).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel H",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "We found that these genes exhibit co-occurrence in all three cohorts (Log2 Odds Ratio > 3, q-Value < 0.001)(Table S1, Fig. 3A, Fig. 3D, Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CDKN2B-AS1, being a non-coding RNA, does not function by encoding proteins but likely participates in the post-transcriptional regulation of CDKN2A and CDKN2B, indirectly affecting the expression regulation of these cell cycle regulatory genes, given their colocation in the same genetic locus (Fig. 1I).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nGenetic Alterations and Expression Correlations of CDKN2A, CDKN2B, and CDKN2B-AS1. (A) Analysis of genetic alterations in CDKN2A, CDKN2B, and CDKN2B-AS1 in the TCGA-GBM cohort. (B, C) Correlation of CDKN2B-AS1 expression with CDKN2A and CDKN2B gene expression in the TCGA-GBM cohort. (D) Analysis of genetic alterations in CDKN2A, CDKN2B, and CDKN2B-AS1 in the TCGA-LGG cohort. (E, F) Correlation of CDKN2B-AS1 expression with CDKN2A and CDKN2B gene expression in the TCGA-LGG cohort.Fig. 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Furthermore, deep deletions significantly reduced the expression of CDKN2A, CDKN2B, and CDKN2B-AS1, aligning with our previous findings(Fig. 3B, C, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarly, CDKN2B-AS1 gene expression is significantly positively correlated with CDKN2B gene expression (Spearman Cor = 0.80, Pearson Cor = 0.83, P < 0.001) and protein expression (Spearman Cor = 0.59, Pearson Cor = 0.63, P < 0.001)(Fig. 4B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We found that these genes exhibit co-occurrence in all three cohorts (Log2 Odds Ratio > 3, q-Value < 0.001)(Table S1, Fig. 3A, Fig. 3D, Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "CDKN2B-AS1, being a non-coding RNA, does not function by encoding proteins but likely participates in the post-transcriptional regulation of CDKN2A and CDKN2B, indirectly affecting the expression regulation of these cell cycle regulatory genes, given their colocation in the same genetic locus (Fig. 1I).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel I",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Furthermore, deep deletions significantly reduced the expression of CDKN2A, CDKN2B, and CDKN2B-AS1, aligning with our previous findings(Fig. 3B, C, E, F).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Similarly, CDKN2B-AS1 gene expression is significantly positively correlated with CDKN2B gene expression (Spearman Cor = 0.80, Pearson Cor = 0.83, P < 0.001) and protein expression (Spearman Cor = 0.59, Pearson Cor = 0.63, P < 0.001)(Fig. 4B-E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "However, these correlations were not consistent across different algorithms and cohorts(Fig. 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The positive correlation of CDKN2B-AS1 with antigen presentation-related genes indicates that high CDKN2B-AS1 expression may enhance tumor cell recognition by the immune system, particularly in LGG, suggesting a specific role in low-grade gliomas(Fig. 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "KEGG pathway analysis showed that the high CDKN2B-AS1 expression group is enriched in apoptosis, DNA replication, adipocytokine signaling, and Toll-like receptor signaling pathways, while the low expression group is enriched in calcium signaling, ErbB signaling, glioma, and long-term depression pathways(Fig. 5C, D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Overall, high CDKN2B-AS1 expression is associated with enhanced cell growth, immune activation, and apoptosis, suggesting a role in tumor progression, whereas low expression is linked to neural signaling processes, potentially affecting the tumor microenvironment.Comparing gene alterations between the two groups revealed no significant differences in frequently mutated genes and chromosomal regions(Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, low CDKN2B-AS1 expression is associated with neural and calcium signaling processes, potentially impacting the neural microenvironment of tumors(Fig. 5F-I).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Immunomodulator analysis also showed inconsistent results regarding the correlation between CDKN2B-AS1 and immune cell infiltration and immune-related pathways in GBM cohorts.In the TCGA-LGG and TCGA-GBM cohorts, we explored the correlation between CDKN2B-AS1 expression and genes related to RNA modifications (m1A, m5C, m6A)(Fig. 6A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "KEGG analysis revealed that the high expression group is enriched in cell cycle, oocyte meiosis, mTOR signaling, DNA replication, and mismatch repair pathways, while the low expression group is enriched in p53 signaling, fatty acid degradation, and drug metabolism-cytochrome P450 pathways(Fig. 6D, E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "CDKN2B-AS1 may enhance tumor cell proliferation through its regulation of DNA replication and cell cycle processes, supported by consistent results across GO, KEGG, and Hallmark analyses.In GBM, the high CDKN2B-AS1 expression group exhibited higher mutation rates in TP53, SPTA1, and RB1, with more frequent copy number losses at 12q.14.1 and 17p.13.1, and more frequent copy number gains at 9p21.3(Fig. 6F).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The consistent results from GO, KEGG, and Hallmark gene set GSEA analyses support the importance of CDKN2B-AS1 in DNA replication, cell cycle regulation, and DNA repair(Fig. 6G-J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel G",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, these correlations were not consistent across different algorithms and cohorts(Fig. 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The positive correlation of CDKN2B-AS1 with antigen presentation-related genes indicates that high CDKN2B-AS1 expression may enhance tumor cell recognition by the immune system, particularly in LGG, suggesting a specific role in low-grade gliomas(Fig. 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "KEGG pathway analysis showed that the high CDKN2B-AS1 expression group is enriched in apoptosis, DNA replication, adipocytokine signaling, and Toll-like receptor signaling pathways, while the low expression group is enriched in calcium signaling, ErbB signaling, glioma, and long-term depression pathways(Fig. 5C, D).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel C",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Comparing gene alterations between the two groups revealed no significant differences in frequently mutated genes and chromosomal regions(Fig. 5E).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel E",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In contrast, low CDKN2B-AS1 expression is associated with neural and calcium signaling processes, potentially impacting the neural microenvironment of tumors(Fig. 5F-I).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel F",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Immunomodulator analysis also showed inconsistent results regarding the correlation between CDKN2B-AS1 and immune cell infiltration and immune-related pathways in GBM cohorts.In the TCGA-LGG and TCGA-GBM cohorts, we explored the correlation between CDKN2B-AS1 expression and genes related to RNA modifications (m1A, m5C, m6A)(Fig. 6A, B, C).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel A",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "KEGG analysis revealed that the high expression group is enriched in cell cycle, oocyte meiosis, mTOR signaling, DNA replication, and mismatch repair pathways, while the low expression group is enriched in p53 signaling, fatty acid degradation, and drug metabolism-cytochrome P450 pathways(Fig. 6D, E).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel D",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In GBM, the high CDKN2B-AS1 expression group exhibited higher mutation rates in TP53, SPTA1, and RB1, with more frequent copy number losses at 12q.14.1 and 17p.13.1, and more frequent copy number gains at 9p21.3(Fig. 6F).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel F",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The consistent results from GO, KEGG, and Hallmark gene set GSEA analyses support the importance of CDKN2B-AS1 in DNA replication, cell cycle regulation, and DNA repair(Fig. 6G-J).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel G",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The results indicate that CDKN2B-AS1 is predominantly enriched in Mono/Macro (10/15), AC-like Malignant (7/15), and Oligodendrocyte (7/15) cells(Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In this spatial transcriptomics dataset, 18 clusters (Morphological adjusted clusters) and 10 cell types (TumorCells, CD4TCells, CD8TCells, NKCells, Macrophages, DCs, Neutrophils, EndothelialCells, Fibroblasts, and CNSCells) were identified(Fig. 7B-D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "This result aligns with our earlier observations that CDKN2B-AS1 expression is positively correlated with antigen presentation-related genes and is localized to Mono/Macro cells at the single-cell level(Fig. 7E-H).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "The results indicate that CDKN2B-AS1 is predominantly enriched in Mono/Macro (10/15), AC-like Malignant (7/15), and Oligodendrocyte (7/15) cells(Fig. 7A).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In this spatial transcriptomics dataset, 18 clusters (Morphological adjusted clusters) and 10 cell types (TumorCells, CD4TCells, CD8TCells, NKCells, Macrophages, DCs, Neutrophils, EndothelialCells, Fibroblasts, and CNSCells) were identified(Fig. 7B-D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "This result aligns with our earlier observations that CDKN2B-AS1 expression is positively correlated with antigen presentation-related genes and is localized to Mono/Macro cells at the single-cell level(Fig. 7E-H).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  }
]